Skip to main content
Download PDF

Erratum to: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin

Breast Cancer Research volume 9, Article number: 401 (2007) Cite this article

The Original Article was published on 26 July 2007

Due to an oversight, the author of the above article [1] was incorrectly listed as having no competing interests. The competing interests section of this article should have read:

References

  1. Colditz GA: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Research. 2007, 9: 108-10.1186/bcr1736.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alvin J Siteman Cancer Center and Department of Surgery, Washington University School of Medicine, Campus Box 8100 660 S Euclid Avenue, St Louis, MO, 63110, USA

    Graham A Colditz

Authors
  1. Graham A Colditz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graham A Colditz.

Additional information

Competing interests

GC has served as an expert witness for plaintiff lawyers preparing hormone therapy litigation. GC has received research support from GlaxoSmithKline, from the American Cancer Society, and from the Breast Cancer Research Foundation. No group or organization funded this manuscript.

The online version of the original article can be found at 10.1186/bcr1736

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Colditz, G.A. Erratum to: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 9, 401 (2007). https://doi.org/10.1186/bcr1786

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/bcr1786

Breast Cancer Research

ISSN: 1465-542X

Contact us